Quarterly Injection Eyed for Myasthenia Gravis
A November FDA decision on Cemdisiran would decide whether this every-three-months therapy reaches patients.
Updated on Nov. 2, 2026 in Biotech
Live Poll
Do you trust the FDA to approve new treatments safely and on time?
The FDA is set to rule in November 2026 on several key drugs, including Regeneron and Alnylam's Cemdisiran for generalized myasthenia gravis, which received Priority Review in June 2026. Cemdisiran is research-stage pending the FDA decision and has not yet been approved.
Why it matters
A November decision would determine whether a quarterly injectable treatment for a rare autoimmune disease reaches patients, shaping how competing biologics and gene-silencing therapies are positioned in the market. The FDA's review of Roche's Gazyva for primary membranous nephropathy, granted Priority Review in July 2026, adds a second near-term regulatory milestone in the same cycle.
The Nimble trial reports a 2.3-point gap in daily functioning change and a 32.5-percentage-point gap in clinically meaningful improvement between Cemdisiran and placebo at 24 weeks. The MAJESTY trial's 36.9% complete remission rate for Gazyva after two years is the reported efficacy figure for that drug in a 142-patient study.
The players
Regeneron
A U.S. biotechnology company known for antibody therapeutics and a leading developer of immunology and neurology drugs, currently developing Cemdisiran.
Alnylam Pharmaceuticals
A biotechnology company that pioneered RNA-interference therapeutics and licenses its platform to partners, including Regeneron for Cemdisiran.
Roche
A Swiss pharmaceutical and diagnostics company with a large oncology and immunology pipeline, developing both Gazyva and Giredestrant.
U.S. Food and Drug Administration
The U.S. federal agency responsible for reviewing and approving drugs, which has granted Priority Review to Cemdisiran and Gazyva and will issue the pending decisions.
The details
Cemdisiran is an RNA-based therapy, a class of drug that uses short RNA molecules to silence a gene's messenger RNA so the body makes less of a target protein. It is administered by injection once every three months, and Regeneron is developing it under license from Alnylam, which holds the underlying RNA-silencing platform. Gazyva, an antibody therapy that targets CD20, a protein on certain immune B cells, is being reviewed for primary membranous nephropathy, a kidney disease in which the immune system attacks the kidney's filtering structures.
Timeline
June 2026: FDA granted Priority Review to Cemdisiran for generalized myasthenia gravis.
July 2026: FDA granted Priority Review to Gazyva for primary membranous nephropathy.
November 2026: FDA decisions expected on Cemdisiran and Gazyva.
November 30, 2026: FDA decision scheduled on Giredestrant.
The Tech Race
Cemdisiran sits in the RNA-interference field pioneered by Alnylam, where Regeneron's license positions it as a challenger to existing myasthenia gravis biologics. The November FDA decision will show whether this gene-silencing approach can move from research-stage development into a commercial alternative in the same cycle as Roche's Gazyva and Giredestrant reviews.
If approved, Cemdisiran would be dosed by injection once every three months, a schedule that could reduce how often patients with myasthenia gravis need treatment visits. Availability, pricing, and launch timing have not been announced, and no approval has been granted.
The takeaway
The FDA's November 2026 rulings on Cemdisiran, Gazyva, and Giredestrant will show whether these late-stage programs convert trial results into approvals. Watch the FDA's November decisions and the November 30 Giredestrant date for the next confirmed milestones.
What happens next
The FDA is expected to rule on Cemdisiran and Gazyva in November 2026, and on Giredestrant on November 30, 2026.
Further reading
For background on the drug-development pipeline behind these reviews, see Biotech coverage.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Do you trust the FDA to approve new treatments safely and on time?
